Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$544 Mln
P/E Ratio
--
P/B Ratio
3.53
Industry P/E
--
Debt to Equity
0.01
ROE
-0.48 %
ROCE
-47.12 %
Div. Yield
0 %
Book Value
3.27
EPS
-0.91
CFO
$-108.12 Mln
EBITDA
$-159.26 Mln
Net Profit
$-142.21 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Capricor Therapeutics (CAPR)
| -0.83 | 6.42 | -5.82 | 183.92 | 63.87 | 47.05 | -16.19 |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Capricor Therapeutics (CAPR)
| 179.83 | 26.68 | 31.74 | -14.58 | 167.97 | -68.78 | -73.86 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 9,808.03 | 20.22 | 23.13 | |
| 295.46 | 8,956.09 | 22.08 | 58.42 | |
| 26.65 | 9,559.25 | -- | -28.77 | |
| 105.01 | 10,030.35 | 30.81 | 14.16 |
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the... United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD. It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California. Address: 10865 Road to the Cure, San Diego, CA, United States, 92121 Read more
Executive Chairman of the Board
Dr. Frank Isaac Litvack FACC, M.D.
Executive Chairman of the Board
Dr. Frank Isaac Litvack FACC, M.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Capricor Therapeutics Inc (CAPR) stood at $ 170 Mln as on 31-Dec-24
The share price of Capricor Therapeutics Inc (CAPR) is $13.69 (NASDAQ) as of 24-Apr-2025 10:43 EDT. Capricor Therapeutics Inc (CAPR) has given a return of 63.87% in the last 3 years.
Capricor Therapeutics Inc (CAPR) has a market capitalisation of $ 544 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Capricor Therapeutics Inc (CAPR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Capricor Therapeutics Inc (CAPR) and enter the required number of quantities and click on buy to purchase the shares of Capricor Therapeutics Inc (CAPR).
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD. It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California. Address: 10865 Road to the Cure, San Diego, CA, United States, 92121
The CEO & director of Dr. Frank Isaac Litvack FACC, M.D.. is Capricor Therapeutics Inc (CAPR), and CFO & Sr. VP is Dr. Frank Isaac Litvack FACC, M.D..
There is no promoter pledging in Capricor Therapeutics Inc (CAPR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Capricor Therapeutics Inc. (CAPR) | Ratios |
|---|---|
|
Return on equity(%)
|
-48.16
|
|
Operating margin(%)
|
-191.13
|
|
Net Margin(%)
|
-181.71
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Capricor Therapeutics Inc (CAPR) was $0 Mln.
$0.54
(
